Mainz Biomed Statistics
Total Valuation
Mainz Biomed has a market cap or net worth of $6.32 million. The enterprise value is $8.44 million.
Important Dates
The last earnings date was Tuesday, March 31, 2026, after market close.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mainz Biomed has 12.52 million shares outstanding. The number of shares has increased by 508.38% in one year.
| Current Share Class | 12.52M |
| Shares Outstanding | 12.52M |
| Shares Change (YoY) | +508.38% |
| Shares Change (QoQ) | +181.43% |
| Owned by Insiders (%) | 13.32% |
| Owned by Institutions (%) | 6.49% |
| Float | 10.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.58 |
| Forward PS | n/a |
| PB Ratio | 8.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.50, with a Debt / Equity ratio of 4.01.
| Current Ratio | 0.50 |
| Quick Ratio | 0.27 |
| Debt / Equity | 4.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.15 |
Financial Efficiency
Return on equity (ROE) is -488.32% and return on invested capital (ROIC) is -132.71%.
| Return on Equity (ROE) | -488.32% |
| Return on Assets (ROA) | -89.61% |
| Return on Invested Capital (ROIC) | -132.71% |
| Return on Capital Employed (ROCE) | -826.08% |
| Weighted Average Cost of Capital (WACC) | 8.11% |
| Revenue Per Employee | $20,657 |
| Profits Per Employee | -$623,489 |
| Employee Count | 26 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.71% in the last 52 weeks. The beta is 0.47, so Mainz Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -84.71% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 49.70 |
| Average Volume (20 Days) | 392,079 |
Short Selling Information
The latest short interest is 684,848, so 5.47% of the outstanding shares have been sold short.
| Short Interest | 684,848 |
| Short Previous Month | 275,109 |
| Short % of Shares Out | 5.47% |
| Short % of Float | 6.31% |
| Short Ratio (days to cover) | 0.84 |
Income Statement
In the last 12 months, Mainz Biomed had revenue of $537,080 and -$16.21 million in losses. Loss per share was -$2.70.
| Revenue | 537,080 |
| Gross Profit | 389,792 |
| Operating Income | -13.50M |
| Pretax Income | -16.21M |
| Net Income | -16.21M |
| EBITDA | -12.88M |
| EBIT | -13.50M |
| Loss Per Share | -$2.70 |
Full Income StatementBalance Sheet
The company has $889,091 in cash and $2.57 million in debt, with a net cash position of -$1.68 million or -$0.13 per share.
| Cash & Cash Equivalents | 889,091 |
| Total Debt | 2.57M |
| Net Cash | -1.68M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 641,600 |
| Book Value Per Share | 0.07 |
| Working Capital | -1.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.98 million and capital expenditures -$1,216, giving a free cash flow of -$10.98 million.
| Operating Cash Flow | -10.98M |
| Capital Expenditures | -1,216 |
| Depreciation & Amortization | 615,720 |
| Net Borrowing | -1.49M |
| Free Cash Flow | -10.98M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | 72.58% |
| Operating Margin | -2,513.37% |
| Pretax Margin | -3,018.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mainz Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -508.38% |
| Shareholder Yield | -508.38% |
| Earnings Yield | -239.95% |
| FCF Yield | -162.54% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | 122.15% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Dec 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
Mainz Biomed has an Altman Z-Score of -34.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -34.99 |
| Piotroski F-Score | 2 |
